43/120
1.8 / 5 stars
All 120 Win/Lose results shown below
TBPH Roast Me summary
Theravance Biopharma, Inc. (TBPH). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
LoseTBPH / S&P 4.74% / 15.20% |
WinTBPH / S&P 35.11% / 15.00% |
WinTBPH / S&P 333.33% / 50.40% |
| 2026-Q11/3 |
LoseTBPH / S&P -13.25% / -4.33% |
WinTBPH / S&P 68.20% / 11.30% |
LoseTBPH / S&P TBPH unavailable / 27.70% |
| 2025-Q42/3 |
WinTBPH / S&P 28.15% / 2.65% |
WinTBPH / S&P 66.92% / 9.00% |
LoseTBPH / S&P TBPH unavailable / 13.40% |
| 2025-Q32/3 |
WinTBPH / S&P 32.37% / 8.12% |
WinTBPH / S&P 27.12% / 4.61% |
LoseTBPH / S&P TBPH unavailable / 13.45% |
| 2025-Q22/3 |
WinTBPH / S&P 23.52% / 10.94% |
WinTBPH / S&P 24.49% / 4.83% |
LoseTBPH / S&P TBPH unavailable / 10.63% |
| 2025-Q11/3 |
LoseTBPH / S&P -5.10% / -4.27% |
WinTBPH / S&P 6.11% / 4.98% |
LoseTBPH / S&P TBPH unavailable / 10.57% |
| 2024-Q42/3 |
WinTBPH / S&P 16.75% / 2.41% |
WinTBPH / S&P 12.12% / 5.25% |
LoseTBPH / S&P TBPH unavailable / 6.15% |
| 2024-Q31/3 |
LoseTBPH / S&P -4.95% / 5.89% |
WinTBPH / S&P 15.93% / 5.89% |
LoseTBPH / S&P TBPH unavailable / 6.11% |
| 2024-Q21/3 |
LoseTBPH / S&P -5.46% / 4.28% |
WinTBPH / S&P 20.97% / 5.38% |
LoseTBPH / S&P -108.03% / 5.12% |
| 2024-Q11/3 |
LoseTBPH / S&P -20.20% / 10.56% |
WinTBPH / S&P 26.65% / 5.71% |
LoseTBPH / S&P -107.41% / 5.59% |
| 2023-Q42/3 |
WinTBPH / S&P 30.24% / 11.69% |
WinTBPH / S&P 11.84% / 6.81% |
LoseTBPH / S&P -108.44% / 7.78% |
| 2023-Q30/3 |
LoseTBPH / S&P -16.62% / -3.27% |
LoseTBPH / S&P 5.55% / 7.52% |
LoseTBPH / S&P -105.41% / -5.03% |
| 2023-Q20/3 |
LoseTBPH / S&P -4.61% / 8.74% |
LoseTBPH / S&P -2.14% / 9.50% |
LoseTBPH / S&P TBPH unavailable / -8.57% |
| 2023-Q10/3 |
LoseTBPH / S&P -3.30% / 7.50% |
LoseTBPH / S&P -10.48% / 10.77% |
LoseTBPH / S&P TBPH unavailable / -15.69% |
| 2022-Q41/3 |
WinTBPH / S&P 10.65% / 7.56% |
LoseTBPH / S&P -7.17% / 11.88% |
LoseTBPH / S&P TBPH unavailable / -17.99% |
| 2022-Q31/3 |
WinTBPH / S&P 11.92% / -4.88% |
LoseTBPH / S&P -12.61% / 13.47% |
LoseTBPH / S&P TBPH unavailable / -1.41% |
| 2022-Q21/3 |
WinTBPH / S&P -5.23% / -16.10% |
LoseTBPH / S&P -18.35% / 13.71% |
LoseTBPH / S&P TBPH unavailable / 11.04% |
| 2022-Q10/3 |
LoseTBPH / S&P -13.48% / -4.60% |
LoseTBPH / S&P -18.12% / 15.97% |
LoseTBPH / S&P TBPH unavailable / 42.23% |
| 2021-Q41/3 |
WinTBPH / S&P 49.32% / 11.03% |
LoseTBPH / S&P -23.03% / 15.00% |
LoseTBPH / S&P TBPH unavailable / 96.40% |
| 2021-Q30/3 |
LoseTBPH / S&P -49.04% / 0.58% |
LoseTBPH / S&P -28.48% / 10.77% |
LoseTBPH / S&P TBPH unavailable / 69.42% |
| 2021-Q20/3 |
LoseTBPH / S&P -28.86% / 8.55% |
LoseTBPH / S&P -16.46% / 6.58% |
LoseTBPH / S&P TBPH unavailable / 51.81% |
| 2021-Q11/3 |
WinTBPH / S&P 14.86% / 6.17% |
LoseTBPH / S&P -24.66% / -1.06% |
LoseTBPH / S&P TBPH unavailable / 7.39% |
| 2020-Q42/3 |
WinTBPH / S&P 20.19% / 12.15% |
WinTBPH / S&P -2.12% / -3.72% |
LoseTBPH / S&P TBPH unavailable / -33.42% |
| 2020-Q31/3 |
LoseTBPH / S&P -29.56% / 8.93% |
WinTBPH / S&P 38.51% / -2.04% |
LoseTBPH / S&P TBPH unavailable / -27.10% |
| 2020-Q21/3 |
LoseTBPH / S&P -9.17% / 20.54% |
WinTBPH / S&P 27.86% / -0.46% |
LoseTBPH / S&P TBPH unavailable / -27.11% |
| 2020-Q12/3 |
WinTBPH / S&P -10.74% / -19.60% |
WinTBPH / S&P 53.23% / 3.47% |
LoseTBPH / S&P TBPH unavailable / -14.75% |
| 2019-Q42/3 |
WinTBPH / S&P 32.91% / 9.07% |
WinTBPH / S&P 21.61% / 5.36% |
LoseTBPH / S&P TBPH unavailable / 2.99% |
| 2019-Q32/3 |
WinTBPH / S&P 19.29% / 1.70% |
WinTBPH / S&P 21.37% / 5.02% |
LoseTBPH / S&P TBPH unavailable / 0.21% |
| 2019-Q21/3 |
LoseTBPH / S&P -27.97% / 4.30% |
WinTBPH / S&P 47.99% / 6.64% |
LoseTBPH / S&P TBPH unavailable / 8.65% |
| 2019-Q11/3 |
LoseTBPH / S&P -11.41% / 13.65% |
WinTBPH / S&P 178.34% / 8.12% |
LoseTBPH / S&P TBPH unavailable / 14.29% |
| 2018-Q41/3 |
LoseTBPH / S&P -21.67% / -13.52% |
WinTBPH / S&P 292.37% / 9.05% |
LoseTBPH / S&P TBPH unavailable / 18.23% |
| 2018-Q32/3 |
WinTBPH / S&P 44.05% / 7.71% |
WinTBPH / S&P 196.73% / 10.21% |
LoseTBPH / S&P TBPH unavailable / 19.06% |
| 2018-Q21/3 |
LoseTBPH / S&P -6.47% / 3.43% |
WinTBPH / S&P 29.40% / 9.03% |
LoseTBPH / S&P TBPH unavailable / 14.46% |
| 2018-Q10/3 |
LoseTBPH / S&P -13.05% / -0.76% |
LoseTBPH / S&P -38.13% / 7.68% |
LoseTBPH / S&P TBPH unavailable / 12.46% |
| 2017-Q40/3 |
LoseTBPH / S&P -18.55% / 6.64% |
LoseTBPH / S&P -68.37% / 7.03% |
LoseTBPH / S&P TBPH unavailable / 13.82% |
| 2017-Q30/3 |
LoseTBPH / S&P -14.06% / 4.48% |
LoseTBPH / S&P -64.65% / 5.68% |
LoseTBPH / S&P TBPH unavailable / 17.57% |
| 2017-Q21/3 |
WinTBPH / S&P 8.20% / 3.09% |
LoseTBPH / S&P -18.48% / 4.83% |
LoseTBPH / S&P TBPH unavailable / 17.74% |
| 2017-Q11/3 |
WinTBPH / S&P 15.50% / 6.07% |
LoseTBPH / S&P -16.97% / 3.67% |
LoseTBPH / S&P TBPH unavailable / 13.32% |
| 2016-Q41/3 |
LoseTBPH / S&P -12.03% / 3.82% |
WinTBPH / S&P 15.48% / 2.09% |
LoseTBPH / S&P TBPH unavailable / 7.05% |
| 2016-Q32/3 |
WinTBPH / S&P 59.72% / 3.85% |
WinTBPH / S&P 18.11% / 0.20% |
LoseTBPH / S&P TBPH unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | TBPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 22.80% | 20.78% |
| Annualized return | 22.80% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | TBPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 106.61% | 83.14% |
| Annualized return | 15.62% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | TBPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -40.94% | 319.30% |
| Annualized return | -5.13% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |